Skip Navigation
Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
AHRQ Home | Questions? | Contact Us | Site Map | What's New | Browse | Información en español | E-mail UpdatesE-mail Updates
 
Slide Tray
0 slides

Return to Slide Library

Slides

Slides: 1–12 of 208
Add to tray Remove from tray

Overview: Results for Prevention

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: overview | prevention | antibiotic restriction | environmental interventions | C. difficile infection (CDI) incidence | outbreaks
Add to tray Remove from tray

Introduction: C.difficile Etiology

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: C. difficile Infection (CDI) | hypervirulent | risk factors | toxigenic | etiology
Add to tray Remove from tray

Assays Commonly Used in CDI Diagnostics

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: C. difficile Infection (CDI) | C. difficile culture | cytotoxicity assay | immunoassays | toxin gene detection | diagnostic assays
Add to tray Remove from tray

Comparative Effectiveness of CDI Prevention Strategies

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: prevention strategies | C. difficile infection (CDI) | antibiotic prescribing policies | institutional strategies | risk factors
Add to tray Remove from tray

What To Discuss With Your Patients

Presentation: Clostridium difficile Infections: Diagnosis, Treatment, and Prevention
Keywords: patients | risk factors | prevention | antibiotic treatment | nonstandard interventions
Add to tray Remove from tray

Factors Affecting Outcomes: Demographic Subgroups

Presentation: Analgesics for Osteoarthritis—An Update
Keywords: CV risk | GI risk | NSAIDs | outcomes | strength of evidence | demographic subgroups
Add to tray Remove from tray

Factors Affecting Outcomes: Pre-existing Disease

Presentation: Analgesics for Osteoarthritis—An Update
Keywords: outcomes | strength of evidence | NSAIDs | GI risk | bleeding
Add to tray Remove from tray

Factors Affecting Outcomes: Concomitant Medication Use

Presentation: Analgesics for Osteoarthritis—An Update
Keywords: bleeding | GI risk | NSAIDs | strength of evidence | ulcer | outcomes
This figure places the key questions on an analytic framework showing the essential decisional points between traumatic brain injury (TBI) and response to treatment for depression. After experiencing a TBI, an individual may be screened for depression at some point. The timing and method of screening constitute one aspect of the research question for this review. Individuals with a diagnosis of depression may then be treated with one or more of the following: psychotropic medications, individual/group psychotherapy, neuropsychological and community-based rehabilitation, complementary or alternative medicine, or neuromodulation therapies. Use of these treatments may result in both short-term and long-term outcomes, such as change in symptom status, harms, need for additional treatment, improvements in quality of life and activities of daily living, and recurrence of symptoms. The risk of an individual for both TBI and depression are influenced by demographics such as age, gender, and occupation. The timing of treatment for TBI, depression screening and treatment, and the outcomes of treatment are all influenced by timing of care initiation, severity of TBI and any concomitant physical injuries, presence of social support, and mental status. Provider factors, such as specialty and experience, the content of the care received, insurance coverage, and organization of services related to treatment for TBI and depression also influence screening, treatment, and outcomes.
Add to tray Remove from tray

Capturing the Context

Presentation: Analytic Frameworks
Keywords: analytic framework | components
Add to tray Remove from tray

Background: Prevalence

Presentation: Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin II Receptor Antagonists (ARBs), or Direct Renin Inhibitors (DRI) for Adults With Hypertension
Keywords: prevalence | hypertension | risk factor | heart | kidneys
Add to tray Remove from tray

Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Pediatric Populations

Presentation: Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Pediatric Populations
Keywords: research evidence | comparative effectiveness review
Add to tray Remove from tray

Background: Juvenile Idiopathic Arthritis

Presentation: Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Pediatric Populations
Keywords: juvenile idiopathic arthritis | chronic inflammatory disease | disease progression | cartilage | bone | soft tissue | severe disability | functional loss | organ failure | death
Pages: [1] 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Next
 
 
 
 
www.ahrq.gov AHRQ Home | Questions? | Contact AHRQ | Site Map | Accessibility | Privacy Policy | Freedom of Information Act | Disclaimers
U.S. Department of Health & Human Services | The White House | USA.gov: The U.S. Government's Official Web Portal

Agency for Healthcare Research and Quality • 540 Gaither Road Rockville, MD 20850 • Telephone: (301) 427-1364